High Rate of Late-Stage Drug Failure Drives Pharma ADMET Testing Market Growth

The global pharma ADMET testing market is expected to grow from US$ 6,783.06 million in 2021 to US$ 13,578.62 million by 2028; it is estimated to grow at a CAGR of 10.5% from 2022 to 2028. The growth of the market is mainly driven by the high rates of late-stage drug failure and increasing approvals and launches of product. Additionally, the rise of new and emerging technologies is likely to emerge as a significant trend in the market during the forecast period. However, the high cost of ADME testing studies hampers the market growth.

ADMET (absorption, distribution, metabolism, excretion, and toxicity) testing is used to determine the safety, uptake, elimination, metabolic behavior, and effectiveness of drugs. Many drug candidates are not approved due to the lack of efficacy and safety. Therefore, testing drugs using ADMET testing becomes important as it helps find efficacious molecules. These drug tests define the impact of a specific drug or chemical on human tissues. Toxicology testing is an important phenomenon before introducing new medicine to the market. ADMET testing facilitates pharmaceutical manufacturing companies to minimize their drug discovery time and testing complications, and reduce the drug development cost.

The disaster of a rising number of therapeutic molecules in the last phases of clinical trials has cost money and valuable time invested in the research and development of new drugs. This has led to the high investments in the development of new technologies for toxicity testing. According to the article "Importance of ADME/Tox in Early Drug Discovery," 2022, in the current drug discovery and development pipeline, only 10 molecules out of 1,000 screened hits are projected to enter the preclinical testing stage, and only 9.6% will enter clinical trials. The drug approval process is projected to take 15 years on average, and phases II and III are the most expensive phases of clinical trials. The pre-approval expenditures for a medicine can be as high as US$ 2.56 billion, which further increases to US$ 2.87 billion in the post-approved stage. According to the study titled "Why 90% of Clinical Drug Development Fails and How to Improve It", 2022, 90% of clinical drug development fails despite the successful implementation of many strategies. After entering clinical investigations, 9 out of 10 drug candidates fail during phase I, II, and III clinical trials, and the drug approval process. Drug candidates rejected in preclinical stages are not included in the 90% failure rate of the drugs in clinical stages, as they don't enter the phase I clinical trials. If preclinical drug candidates are included, the failure rate of drug discovery and development rises even higher than 90%. According to analyses of clinical trial data from 2010 to 2017, lacking clinical effectiveness (40-50%), uncontrollable toxicity (30%), poor drug-like qualities (10-15%), no commercial needs, and ineffective strategic planning (10%) are the four major causes of trial failure.

New drug development is both resource and time-intensive, where later clinical stages result in significant costs. The discovery and development of each new medicine that is approved for clinical use is a lengthy, expensive, and challenging process that takes over 10-15 years and costs on average over US$ 1-2 billion. To lower the attrition rate in drug research & development, it is crucial to filter and optimize the absorption, distribution, metabolism, elimination, and toxicity (ADMET) characteristics of pharmaceuticals at an early stage. It has been widely accepted that drug ADMET properties should be considered as early as possible to reduce failure rates in the clinical phase of drug discovery. In vitro and in vivo drug evaluation techniques have reached maturity in preclinical applications, and in silico technologies are gaining vast acceptance to evaluate the relevant properties of drugs in the preclinical stage. The development of software programs and in silico models is further promoting the implementation of ADMET studies. Thus, the increasing need for ADME testing in drug development boosts the pharma ADME testing market.

CMIC HOLDINGS Co., LTD; Charles River Laboratories; WuXi AppTec; Promega Corporation; MERCK KGaA; Agilent Technologies, Inc.; Biovia (Dassault System

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id:sales@premiummarketinsights.com